You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Oncology
Novartis to build new radioligand therapy site in Texas
Login
Username:

Password:


Related Headlines

FDA accepts Genentech application for giredestrant combination in ESR1-mutated advanced breast cancer

EMA validates Enhertu application for post-neoadjuvant HER2-positive early breast cancer

IBA and Shreeji sign agreement to deploy four cyclotrons for PET radiopharmaceuticals in India

AVEO Oncology completes first interim analysis in global Phase 3 FIERCE-HN study

Liminatus Pharma prices USD4.0m public offering

First Ascent Biomedical opens Functional Precision Medicine cancer lab in Miami

Nucleome Therapeutics names new chief scientific officer

Eli Lilly and Company reports positive Phase 3 LIBRETTO-432 results for Retevmo in early-stage RET fusion-positive NSCLC

Ella immunoassay platform gains CE‑IVD approval in the EU

HanchorBio's HCB101 receives US FDA Orphan Drug Designation in gastric cancer

Innovent reports first participant dosed in Phase 3 trial of IBI354 for first-line treatment of HER2-positive breast cancer

Celyad Oncology sells C-Cathez catheter to CellProthera

Citius Oncology signs LYMPHIR distribution agreement with Uniphar

IP Group plc portfolio company Microbiotica reports positive Phase 1b data for MB310 in ulcerative colitis

Ribo and Madrigal sign global siRNA licensing deal

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026